Dr. Armin Rashidi, MD

Dr. Rashidi practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Rashidi's NPI, 1285950089, was assigned on April 19, 2010. Dr. Rashidi holds Washington license MD61247742.

Dr. Rashidi's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Rashidi's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. Dr. Rashidi is also affiliated with UW Medical Center - Montlake. The medical group on file is UW Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rashidi practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rashidi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rashidi is licensed in Washington.

CMS data shows 274 Medicare services from Dr. Rashidi across 5 procedure codes in 2024, for 45 Medicare patients. Medicare paid $25,720 for them.

CMS counts 45 Medicare patients who saw Dr. Rashidi in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have high blood pressure, and 71% have high cholesterol. Their average risk score is 3.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rashidi's median patient age at 64, with 42% women.

In 2023, Dr. Rashidi wrote 11 Medicare Part D claims. They cover 1 drug, with $296 in total drug cost. In 2022, CMS named 77 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Rashidi for performance year 2024, reported through an alternative payment model (APM). Dr. Rashidi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rashidi as offering telehealth.

Dmand AI links 212 papers to Dr. Rashidi, published from 2005 to 2025. 2019 was the busiest year, with 19. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Gastrointestinal Microbiome. Dr. Rashidi has published most often in Bone Marrow Transplant. Dr. Rashidi's most frequent co-authors are Daniel J. Weisdorf, MD, Maryam Ebadi, MD and Alexander Khoruts, MD.

Dmand AI links Dr. Rashidi to 1 clinical trial. Conditions studied include Cytomegalovirus Infections and Leukemia, Myeloid, Accelerated Phase.

CMS Open Payments shows 10 general payments to Dr. Rashidi from 2 drug and device companies from 2018 to 2020. Consulting fees make up the largest share, 72% of the total. Incyte Corporation paid the most, $4,146.